R&D

R&D is the backbone of Lilly

Lilly Research Laboratories (LRL) discover and develop high-quality innovative medicines that help patients live longer, healthier, happier lives. This is done in a reliable and cost-effective manner and in an atmosphere of optimism, teamwork, quality and compliance.

Since 2002, Lilly has registered all Lilly-sponsored Phase II, Phase III and Phase IV clinical studies, conducted anywhere in the world that were initialited on or after October 15, 2002 on www.clinicaltrials.gov. Additionally, Lilly began registering all Phase I clinical studies commencing on or after October 1, 2010.

Our investment in research and development has been sustained at a high level over many years and has resulted in one of the most prolific pipelines in the industry, with more than 60 potential medicines currently in development.

The UK has played a big role in these advancements. The Lilly Research Centre was founded in Windlesham, Surrey in 1967. Since then, it has become a centre of excellence in neuroscience research. Our greatest success to date is the discovery of olanzapine (Zyprexa) which was launched in 1996 and has proved to be the most successful medicine in the history of the company.

Today, over 600 people, representing 45 different nationalities and 30 different functional disciplines, work at Erl Wood on both discovery and development of the new potential medicines in the pipeline. Our research teams continue the quest for new medicines for neurodegenerative disorders, cognitive diseases and more recently sleep disorders.